Richard Hausmann, Elekta President and CEO
Elekta announced on May 19 that it will further develop its focus on cancer care providers and their patients through its acquisition of Kaiku Health. The Finnish company is best known for its app that monitors patient-reported outcomes, providing intelligent symptom tracking and management for healthcare providers in routine oncology care and studies.
The Kaiku Health app screens for patients’ symptoms, notifies the care team on their development and provides value-based personalized support for patients. It is easily implemented into existing hospital information systems and can be integrated with Elekta’s Mosaiq Oncology Information System (OIS). This makes Kaiku Health a valuable tool for healthcare teams to collate patient-recorded feedback and act immediately if anything unusual is reported.
Richard Hausmann, Elekta President and CEO, says: “Including intelligent patient-monitoring software in the Elekta portfolio supports the company’s oncology informatics strategy. This is a concrete step towards expanding our digital portfolio to further digitally connect our two most important stakeholders: our customers and their patients. Kaiku Health’s solution has demonstrated it can improve quality of life and reduce costs of healthcare.”
Lauri Sippola, Kaiku Health CEO and Co-Founder adds: “This is a very exciting step for Kaiku Health, but also for Elekta’s network of thousands of customers. Together we will continue to develop personalized digital interventions in order to help improve the lives of cancer patients globally. Measuring what matters to patients is paramount in value-based healthcare and it will benefit patients, healthcare providers and society.”
Kaiku Health has modules for more than 25 types of cancer across different cancer care pathways. It is currently in use in over 40 European cancer clinics and hospitals. The acquisition took effect May 15, 2020 with Elekta owning 100 percent of Kaiku Health.Back To Top
Elekta Acquires Kaiku, Strengthens Digital Offerings. Appl Rad Oncol.